Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 5/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348952 | 0.92 | CYP11B2 (0.47) | GPR119OPRD1OPRK1NAMPTHIF1A | |
| SCHEMBL240381 | 0.86 | TSHR (0.57) | GPR119OPRD1OPRK1ALOX15TSHR | |
| SCHEMBL23647585 | 0.85 | JAK2 (0.48) | GPR119OPRD1OPRK1NAMPTHIF1A | |
| SCHEMBL18432250 | 0.84 | ESR2 (0.48) | GPR119OPRD1OPRK1ALOX15TSHR | |
| SCHEMBL11956931 | 0.84 | GPR119 (0.53) | GPR119OPRD1OPRK1ALOX15TSHR | |
| SCHEMBL1815376 | 0.84 | GPR119 (0.45) | GPR119OPRD1OPRK1ALOX15TSHR | |
| SCHEMBL2629481 | 0.84 | ALDH1A1 (0.60) | GPR119OPRD1OPRK1NAMPTCYP2C9 | |
| SCHEMBL6795066 | 0.84 | MAPT (0.55) | GPR119OPRD1OPRK1DRD2 | |
| SCHEMBL8352820 | 0.84 | TSHR (0.53) | GPR119OPRD1OPRK1NAMPTHIF1A | |
| SCHEMBL12561460 | 0.83 | DRD2 (0.46) | GPR119OPRD1OPRK1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | GPR119 4038/4885OPRD1 4692/4885OPRK1 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.